NRSN — Neurosense Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $13.20m
- $12.52m
Annual cashflow statement for Neurosense Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.22 | -2.83 | -4.04 | -12.3 | -11.3 |
| Depreciation | |||||
| Non-Cash Items | 0.611 | 2.06 | 2.23 | 3.94 | 0.421 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.029 | 0.069 | 0.273 | 0.726 | 2.31 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -0.582 | -0.695 | -1.54 | -7.59 | -8.45 |
| Capital Expenditures | -0.007 | -0.009 | -0.017 | -0.07 | -0.029 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.019 | — | 0 | -3.47 | 3.67 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.026 | -0.009 | -0.017 | -3.54 | 3.65 |
| Financing Cash Flow Items | — | — | 0.8 | -0.096 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.42 | 0.508 | 11.9 | 3.69 | 3.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.809 | -0.196 | 10.4 | -7.52 | -0.903 |